Core Viewpoint - Yibai Pharmaceutical (600594) announced the suspension of production and sales of its pediatric cough syrup due to a notice from the Guizhou Provincial Drug Administration, but has since resumed operations after rectification, with no significant impact expected on the company's performance [1] Group 1 - On August 2025, the company received a notice from the Guizhou Provincial Drug Administration to suspend production and sales of its pediatric cough syrup [1] - The company immediately halted production and sales upon receiving the notice [1] - After rectification, the company received a notice on September 16, 2025, lifting the suspension, allowing it to resume production and sales [1] Group 2 - The company anticipates that the suspension will not have a significant impact on its overall performance [1]

Core Viewpoint - The company plans to sell a total of 8.686 million shares of Guizhou Yibai Pharmaceutical, 970,600 shares of Aorui De, 7,716 shares of China Ping An, and 4.7122 million shares of Hunan Erkang Pharmaceutical, aiming to optimize its asset structure and improve liquidity and efficiency [1] Group 1 - The estimated profit from the sale of these stocks, after deducting costs and taxes, is expected to exceed 50% of the company's audited net profit for the last year [1] - The sale is intended to enhance the company's asset liquidity and utilization [1] - The company is strategically timing the sale based on stock market conditions [1]

Core Viewpoint - The company plans to sell a significant number of shares in various companies based on market conditions, which is expected to yield substantial profits exceeding 50% of its audited net profit from the last year [1] Group 1: Share Sales - The company intends to sell 8.686 million shares of Guizhou Yibai Pharmaceutical Co., Ltd. [1] - The company plans to sell 970,600 shares of Aorui De Optoelectronics Co., Ltd. [1] - The company will sell 7,716 shares of China Ping An Insurance (Group) Company [1] - The company aims to sell 4.7122 million shares of Hunan Erkang Pharmaceutical Co., Ltd. [1] Group 2: Financial Impact - The estimated profit from the sale of these shares, after deducting holding costs and related taxes, is projected to account for over 50% of the company's audited net profit from the previous year [1]

Core Viewpoint - The company plans to sell a significant number of shares in various companies based on market conditions, with potential gains expected to exceed 50% of its audited net profit from the last year [1] Group 1: Planned Share Sales - The company intends to sell 8.686 million shares of Yibai Pharmaceutical (600594) [1] - The company plans to sell 970,600 shares of Aorui De (600666) [1] - The company will sell 7,716 shares of China Ping An [1] - The company aims to sell 4.7122 million shares of Erkang Pharmaceutical (300267) [1] Group 2: Financial Implications - The expected gains from the share sales, after deducting holding costs and related taxes, are projected to account for over 50% of the company's audited net profit from the previous year [1] - The transaction details, including the ability to complete the sales and the specific timing and pricing, remain uncertain and will require shareholder approval [1]

Meeting Overview - The first extraordinary general meeting of shareholders was held on September 5, 2025, at the administrative building of Guizhou Yibai Pharmaceutical Co., Ltd [2] - The meeting was chaired by the chairman, Ms. Dou Qiling, and utilized a combination of on-site and online voting methods, complying with the Company Law and the Articles of Association [2] Attendance and Voting - All current directors (6), supervisors (3), and the board secretary attended the meeting, with other senior executives present as well [3] - There were no rejected resolutions during the meeting [2] Resolutions Passed - The following resolutions were approved: 1. Cancellation of the Supervisory Board [3] 2. Amendments to the Articles of Association [3] 3. Amendments to the Rules of Procedure for Shareholders' Meetings [3] 4. Amendments to the Rules of Procedure for Board Meetings [4] 5. Amendments to the Independent Director Work System [4] 6. Amendments to the Compensation Management System for Directors and Senior Management [4] 7. Amendments to the Special System for Preventing the Controlling Shareholder and Related Parties from Occupying Company Funds [4] 8. Amendments to the External Investment Management System [4] 9. Amendments to the External Guarantee Management System [4] 10. Amendments to the Related Party Transaction Decision-Making System [4] 11. Amendments to the Fundraising Management Measures [5] 12. Amendments to the Entrusted Financial Management System [5] 13. Amendments to the Special System for Appointing Accounting Firms [5] 14. Amendments to the Implementation Rules for Cumulative Voting [5] Legal Verification - The meeting was witnessed by Beijing Junzhi Law Firm, confirming that the convening and proceedings of the meeting complied with relevant laws and regulations [6] - The resolutions made during the meeting were deemed legal and valid [6]

Core Points - Yibai Pharmaceutical announced the approval of multiple proposals at its first extraordinary general meeting of shareholders in 2025, including the proposal to abolish the supervisory board [2] Group 1 - The company held its first extraordinary general meeting of shareholders in 2025 on September 5 [2] - The proposal to cancel the supervisory board was among the key resolutions passed during the meeting [2]

Core Viewpoint - The legal opinion confirms that the procedures for convening and holding the 2025 First Extraordinary General Meeting of Guizhou Yibai Pharmaceutical Co., Ltd. comply with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][10]. Group 1: Meeting Procedures - The company announced the meeting on August 21, 2025, and published relevant materials on August 28, 2025, in compliance with legal requirements [2][3]. - The meeting was scheduled for September 5, 2025, and was conducted using a combination of on-site and online voting methods [3][4]. - The notice included details such as meeting type, time, location, and voting procedures, meeting the requirements of the Company Law and other regulations [4][9]. Group 2: Attendance and Qualifications - Shareholders registered by the close of trading on August 29, 2025, were eligible to attend the meeting, along with company directors, supervisors, and legal representatives [5][6]. - A total of 348 participants attended the meeting, representing 187,535,236 shares, which is approximately 1.06% of the total shares [5][6]. Group 3: Voting Procedures and Results - The meeting's voting was conducted through a named voting method, with all proposed resolutions receiving overwhelming support, with approval rates ranging from 98.11% to 98.65% [6][8]. - All resolutions, including the cancellation of the supervisory board and amendments to various internal regulations, were passed [7][8][9]. - The voting process and results were verified to be in accordance with the Company Law and other relevant regulations, confirming the legitimacy of the meeting's outcomes [9][10].

Meeting Overview - The shareholder meeting of Guizhou Yibai Pharmaceutical Co., Ltd. was held on September 5, 2025, at the company's administrative building meeting room [1] - The meeting was chaired by the chairman, Ms. Dou Qiling, and utilized a combination of on-site and online voting methods, complying with the Company Law and the company's articles of association [1] Voting Results - All proposed resolutions were passed with significant majority votes, with A-shareholders showing high approval rates ranging from 98.1052% to 98.6529% across various resolutions [2][3] - Specific voting results included: - 193,042,393 votes in favor (98.5460%), 2,681,326 against (1.3687%), and 166,900 abstentions (0.0853%) for one resolution [1] - 192,934,793 votes in favor (98.4910%), 2,760,626 against (1.4092%), and 195,200 abstentions (0.0998%) for another resolution [2] Legal Compliance - The meeting's procedures were confirmed to be in accordance with the Company Law, Shareholder Meeting Rules, and other relevant legal documents, ensuring the legitimacy of the resolutions passed [3]

北京市君致律师事务所 关于贵州益佰制药股份有限公司 2025 年第一次临时股东大会 法 律 意 见 书 北京·东城区北三环东路 36 号环球贸易中心 B 座 11 层 100013 电话（Tel）：010-52213236/52213237/52213238/52213239 北京市君致律师事务所 本所律师根据相关法律、法规和规范性文件的要求，按照律师行业公认的 业务标准、道德规范和勤勉尽责精神，出具法律意见如下： 一、本次股东大会的召集、召开程序 （一）经本所律师核查，公司于 2025 年 8 月 19 日召开的第八届董事会第十 关于贵州益佰制药股份有限公司 2025 年第一次临时股东大会 法律意见书 致：贵州益佰制药股份有限公司 北京市君致律师事务所（以下简称"本所"）接受贵州益佰制药股份有限公 司(以下简称"益佰制药"或"公司")的委托，指派律师出席益佰制药 2025 年 第一次临时股东大会（以下简称"本次股东大会"）。根据《中华人民共和国证券 法》(以下简称"《证券法》")、《中华人民共和国公司法》(以下简称"《公司法》") 和《上市公司股东会规则》(以下简称"《股东会规则》")、《上海证券交易所上 ...

证券代码：600594 证券简称：益佰制药 公告编号：2025-028 贵州益佰制药股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 5 日 (二)股东大会召开的地点：贵州益佰制药股份有限公司行政楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 348 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 195,890,619 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 24.9735 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长窦啟玲女士主持，会议采用现场投 票与网络投票相结合的方式进行表决，本次会议的召集、召开和表决方式符合《公 司法》及《公司章程》 ...